Tumor suppressor gene on chromosome 11
Rare disease
No
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Tumor suppressor gene on chromosome 11
- tumor suppressor gene on chromosome 11
- nonsmall cell lung cancer
- tumor suppressor Gene on chromosome type 11
- tumor suppressor gene on chromosome 11
- tumour suppressor Gene on chromosome type 11
- Severity
- Unknown
- Genetic
- Hereditary
- MONDO ID
- MONDO:0011282
- Parent condition
- MONDO:0003847
Related records
Broader conditions (5)
- Disease
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Hereditary disease
- Human disease
Trials (137)
- [18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients
- A Mobile Supportive Care App for Patients With Metastatic Lung Cancer
- A Multicenter Cancer Biospecimen Collection Study
- A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
- A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
- A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients
- A Radiomic Model for Risk of Local Recurrence and DFS for T3 and T4 Non-small Cell Lung Cancer
- A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
- A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC
- A Randomized Study of Primary Tumor Radiotherapy for Patients With Stage Ⅳ NSCLC
- A Study of [14C]GB491 in Male Healthy Subjects
- A Study of ASN007 in Patients With Advanced Solid Tumors
- A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
- A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
- A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
- A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC
- A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery
- Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
- Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
- Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer